DUBLIN, Aug 12 (Reuters) - Glanbia is cautious about
whether it can hit the upper end of its 17-22% earnings per
share forecast growth range for 2021 due to the possible impact
of price increases planned for the second half of the year, its
chief financial officer said.
"One of the things that we are mindful of is when you put
price increases through, there could be some price elasticity
impacts in the fourth quarter so we are being a bit cautious
about that," Mark Garvey told Reuters after the Irish
nutritional supplement firm released its financial results for
the first six months of 2021.
(Reporting by Conor Humphries; editing by Jason Neely)